Novel Gd(III)-based probes for MR molecular imaging of matrix metalloproteinases

Contrast Media and Molecular Imaging

Volumn 7, Issue 2, 2012, Pages 175-184

  Gringeri, Concetta V ^a   Menchise, Valeria ^b   Rizzitelli, Silvia ^b   Cittadino, Evelina ^b   Catanzaro, Valeria ^b   Dati, Gabriele ^c   Chaabane, Linda ^c   Digilio, Giuseppe ^a   Aime, Silvio ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Contrast agent; Gadolinium; Matrix metalloproteinase; Mouse melanoma; MRI; Tumor

Indexed keywords

ALBUMIN; BETA CYCLODEXTRIN DERIVATIVE; GADOLINIUM; GELATINASE A; ILOMASTAT; MACROPHAGE ELASTASE; TETRAPEPTIDE; TETRAXETAN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR MICROENVIRONMENT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DISEASE MODELS, ANIMAL; GADOLINIUM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; MELANOMA; MICE; MICE, INBRED C57BL; MOLECULAR IMAGING; MOLECULAR PROBES; SOLID-PHASE SYNTHESIS TECHNIQUES;

EID: 84858715144     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.478     Document Type: Article

References (42)

1. Nagase HH, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491-21494.
2. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075-1095.
3. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003; 22: 55-61.
4. Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Ther Targets 2000; 4: 609-633.
5. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
6. Lampert K, Machein U, Machein MR, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 1998; 153: 429-437.
7. Van de Wiele C, Oltenfreiter R. Imaging probes targeting matrix metalloproteinases. Cancer Biother Radiopharm 2006; 21(5): 409-417.
8. 18F]-Marimastat-aryltrifluoroborate as a probe for in vivo PET imaging in cancer. Cancer Res 2010; 70(19): 7562-7569.
9. 18F-labelled derivative of the MMP inhibitor CGS27023A for PET: radiosynthesis and initial small-animal PET studies Applied Radiat Isotopes 2009; 67: 606-610.
10. Wagner S, Breyholz H-J, Law MP, Faust A, Höltke C, Schröer S, Haufe G, Levkau B, Schober O, Schäfers M, Kopka K. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 2007; 50: 5752-5764.
11. Lancelot E, Amirbekian V, Brigger I, Raynaud J-S, Ballet S, David C, Rousseaux O, Le Greneur S, Port M, Lijnen HR, Bruneval P, Michel J-B, Ouimet T, Roques B, Amirbekian S, Hyafil F, Vucic E, Gilberto J, Aguinaldo S, Corot C, Fayad ZA. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008; 28: 429-436.
12. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol 2001; 19: 661-667.
13. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 2001; 276(23): 20572-20578.
14. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW. A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 2002; 277(6): 4485-4491.
15. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008; 27: 679-690.
16. Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Pepin C, Gore JC, Matrisian LM, McIntyre JO. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel MRI contrast agent with a solubility switch. Mol Imag 2007; 6: 393-403.
17. Jastrzebska B, Lebel R, Therriault H, McIntyre JO, Escher E, Guerin B, Paquette B, Neugebauer WA, Lepage M. New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging. J Med Chem 2009; 52: 1576-1581.
18. Lebel R, Jastrzebska B, Therriault H, Cournoyer M-M, McIntyre JO, Escher E, Neugebauer W, Paquette B, Lepage M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn Reson Med 2008; 60: 1056-1065.
19. Mulder WJM, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, Koning GA, Nicolay K. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem 2004; 15: 799-806.
20. Mulder WJM, Strijkers GJ, van Tilborg GAF, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006; 19: 142-164.
21. Park K, Lee S, Kang E, Kim K, Choi K, Kwon IC. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater 2009; 19: 1553-1566.
22. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Advanced Drug Deliv Rev 2010; 62(11): 1052-1063.
23. Sharon Stack M, Gray RD. Comparison of vertebrate collagenase and gelatinase using new fluorogenic substrate peptide. J Biol Chem 1989; 264(8): 4277-4281.
24. Berman J, Green M, Sugg E, Anderegg R, Millington DS, Norwood DL, McGeehan J, Wiseman J. Rapid optimization of enzyme substrates using defined substrate mixtures. J Biol Chem 1992; 267(3): 1434-1437.
25. Deng S-J, Bickett DM, Mitchell JL, Lamberti MH, Blackburn RK, Carter HL, Neugebauer J, Pahel G, Weiner MP, Moss ML. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 2000; 275(40): 31422-31427.
26. Delli Castelli D, Gianolio E, Geninatti Crich S, Terreno E, Aime S. Metal containing nanosized systems for MR-molecular imaging applications. Coord Chem Rev 2008; 252: 2424-2443.
27. Falvey P, Lim CW, Darcy R, Revermann T, Karst U, Giesbers M, Marcelis ATM, Lazar A, Coleman AW, Reinhoudt DN, Ravoo BJ. Bilayer vesicles of amphiphilic cyclodextrins: host membranes that recognize guest molecules. Chem Eur J 2005; 11: 1171-1180.
28. Digilio G, Menchise V, Gianolio E, Catanzaro V, Carrera C, Napolitano R, Fedeli F, Aime S. Exofacial protein thiols as a route for the internalization of Gd(III)-based complexes for MRI cell labelling. J Med Chem 2010; 53: 4877-4890.
29. Carrera C, Digilio G, Baroni S, Burgio D, Consol S, Fedeli F, Longo D, Mortillaro A, Aime S. Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds. Dalton Trans 2007; (43): 4980-4987.
30. Geninatti Crich S, Cabella C, Barge A, Belfiore S, Ghirelli C, Lattuada L, Lanzardo S, Mortillaro A, Tei L, Visigalli M, Forni G, Aime S. In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. J Med Chem 2006; 49: 4926-4936.
31. De Leòn-Rodrìguez LM, Ortiz A, Weiner AL, Zhang S, Kovacs Z, Kodadek T, Sherry AD. Magnetic resonance imaging detects a specific peptide-protein binding event. J Am Chem Soc 2002; 124: 3514-3515.
32. Aime S, Botta M, Terreno E. Gd(III)-based contrast agents for MRI. Adv Inorg Chem 2005; 57: 173-237.
33. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) Chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-2352.
34. III Chelates. J Am Chem Soc 2010; 132: 7836-7837.
35. Zhang Z, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Edn 2005; 44: 6766-6769.
36. 17O NMR relaxometric investigations on two gadolinium(III) DTPA-like chelates endowed with high binding affinity to human serum albumin. J Biol Inorg Chem (JBIC) 1999; 4: 766-774.
37. Rasmussen HS, McCann PP. Matrix Metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69-75.
38. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez, Schaeffer ME, Stack R, Sullivan M, Summers B, Tressler R, Tyrrell D, Wee J, Allen SD, Castellot JJ, Barletta JP, Schultz GS, Fernandez LA, Fisher S, Cui T-Y, Foellmer HG, Grobelny D, Holleran WM. Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 1994; 732: 315-323.
39. Watt AP. Mast cells and peptide induced histamine release. Immunopharmacology 2002; 9: 421-434.
40. Digilio G, Bracco C, Barbero L, Chicco D, Del Curto MD, Esposito P, Traversa S, Aime S. NMR Conformational analysis of antide, a potent antagonist of the gonadotropin releasing hormone. J Am Chem Soc 2002; 124: 3431-3442.
41. Nicolle GM, Merbach AE. Destruction of perfluoroalkyl surfactant aggregates by β-cyclodextrin. Chem Commun 2004; (7): 854-855.
42. Meding J, Urich M, Licha K, Reinhardt M, Misselwitz B, Fayad ZA, Weinmann H-J. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with gadofluorine M. Contrast Media Mol Imag 2007; 2: 120-129.